LitPRO
At the FDA’s request in 2014, Allergan voluntarily recalled its line of Biocell textured breast implants and implantable tissue stretchers. The FDA requested the recall over concerns that the implants were associated with the onset of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare type of non-Hodgkin lymphoma that can develop in scar tissue or fluid around a breast implant. BIA-ALCL is not breast cancer; rather, it is a form of immune system cancer. Its symptoms include persistent pain, swelling, lumps, fluid collection, and unexpected changes in breast shape.
Since the recall, plaintiffs have filed about 1,200 individual lawsuits against Allergan over the implants. Those suits have been merged into a multidistrict litigation (MDL) before the U.S. District Court for the District of New Jersey. Plaintiffs allege that the implants are linked to BIA-ALCL and that the company filed to warn patients about the devices’ risks.
Plaintiffs are seeking compensation for the costs of having their implants surgically removed, replacement implants, treatment for complications, medical monitoring, and more. Some plaintiffs may seek punitive damages. All types of healthcare liens are possible pending the outcome of these cases.
